NDAINTRAVENOUSSOLUTION
Approved
Jul 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
MIDAZOLAM IN 0.8% SODIUM CHLORIDE (midazolam) by Hikma is short-acting benzodiazepine central nervous system (cns) depressant. First approved in 2022.
Drug data last refreshed 16m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Midazolam in 0.8% sodium chloride is a short-acting benzodiazepine CNS depressant administered intravenously as a ready-to-use solution. It is indicated for sedation, anxiolysis, and amnesia in clinical settings such as anesthesia induction, procedural sedation, and intensive care. The product works by enhancing GABA-mediated inhibitory neurotransmission in the central nervous system.
Peak
Product is in peak commercial phase post-approval, with moderate competitive pressure (30%) indicating established market positioning and potential for stable team expansion in field and marketing roles.
Mechanism of Action
short-acting benzodiazepine central nervous system (CNS) depressant.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
Started May 2026
24 enrolled
Advanced Malignancies
A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.
Started Apr 2026
12 enrolled
Healthy Volunteers
A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007)
Started Mar 2026
28 enrolled
Healthy
A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
Started Jan 2026
Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants
Started Oct 2025
28 enrolled
Healthy Adult Participants
Worked on MIDAZOLAM IN 0.8% SODIUM CHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.